Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light

• US 7,901,673 B2
• Filed: 08/25/2003
• Issued: 03/08/2011
• Est. Priority Date: 06/02/2000
• Status: Expired due to Fees

• Current Assignee: Terumo BCT Biotechnologies, LLC (Terumo Corporation)
• Original Assignee: Caridianbct Biotechnologies LLC (Baxter International Inc.)
• Inventors: Keil, Shawn D., Lockerbie, Robert Owen, Kumar, Vijay, Goodrich, Raymond P.
• Primary Examiner(s): Noakes; Suzanne M
• Assistant Examiner(s): Lee; Jae W
• Application Number:
  US10/648,536
• Publication Number:
  US 20040081956A1
• Time in Patent Office: 2,752 Days
• Field of Search: None
• US Class Current: 424/93.71
• CPC Class Codes: A61K 41/17 by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
• CPC Class Codes: A61L 2/0011 using physical methods
• CPC Class Codes: A61L 2/0082 using chemical substances
• CPC Class Codes: A61L 2/0088 Liquid substances
• CPC Class Codes: A61L 2/08 Radiation
• CPC Class Codes: A61L 2/084 Visible light
• CPC Class Codes: A61L 2/10 Ultraviolet radiation
• CPC Class Codes: A61L 2202/22 Blood or products thereof
• CPC Class Codes: A61M 1/0213 with isolated sections of the tube used as additive reservoirs
• CPC Class Codes: A61M 1/3681 by irradiation
• CPC Class Codes: A61M 1/3683 using photoactive agents
• CPC Class Codes: A61M 1/3693 using separation based on different densities of components, e.g. centrifuging
• CPC Class Codes: A61M 2205/123 with incorporated reservoirs

Abstract

A process for damaging and maintaining damage to the nucleic acids of pathogens such as white blood cells, bacteria and viruses which may be contained in blood or blood components. This process comprises adding to the blood or blood component containing pathogens an effective amount of riboflavin, and exposing the fluid to light of an appropriate wavelength to damage the nucleic acid of the pathogen and to substantially maintain the damage to the pathogenic nucleic acids to allow for subsequent transfusion into a recipient.

Claims

1. A process for inactivating white blood cells which may be contained in a fluid comprising:

(a) adding riboflavin at concentration between 50-500 μ

M to the fluid containing white blood cells; and

(b) exposing the fluid of step (a) to light in the UVB range to activate the riboflavin and cause damage to the nucleic acid of the white blood cells thereby substantially maintaining the damage to the nucleic acids of the white blood cells, wherein the inactivated white blood cells of step (b) are unable to reactivate upon storage or infusion into a patient.

2. The process of claim 1 wherein the fluid further comprises red blood cells.

3. The process of claim 1 wherein the fluid further comprises platelets.

4. The process of claim 1 wherein the fluid further comprises plasma.

6. A fluid suitable for transfusing into a patient comprising red blood cells treated by the process of claim 1.

7. A fluid suitable for transfusing into a patient comprising platelets treated by the process of claim 1.

8. A fluid suitable for transfusing into a patient comprising plasma treated by the process of claim 1.

5. A process for providing pathogen-reduced blood or blood components comprising:

(a) damaging the nucleic acid of any pathogenic white blood cells which may be present with the blood or blood components by adding riboflavin at a concentration between 50-500 μ

M to the blood or blood components; and

(b) exposing the blood or blood components of step (a) to light in the UVB range or visible light to activate the riboflavin to fragment the nucleic acid of the pathogenic white blood cells, wherein the pathogenic white blood cells of step (b) are unable to reactivate upon storage or infusion into a patient.